Parkinson's Disease Levodopa-Induced Dyskinesia (LID) Market was valued at USD 410 million in 2024 and is expected to reach USD 760 million by 2034

Market Overview
The Parkinson's Disease Levodopa-Induced Dyskinesia (LID) Market was valued at USD 410 million in 2024 and is expected to reach USD 760 million by 2034, growing at a CAGR of 6.3% during the forecast period.
Levodopa-induced dyskinesia is one of the most challenging motor complications of long-term levodopa therapy in Parkinson's disease (PD). It manifests as involuntary, repetitive, and often disabling movements that significantly impact quality of life.

Growing global prevalence of Parkinson's disease, rising adoption of levodopa therapy, increased demand for adjunctive treatments, and expanding research into glutamatergic and serotonergic pathways are major drivers of market growth. The approval of targeted LID therapies and ongoing clinical trials further strengthen the market outlook.

Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71914

Market Dynamics
Drivers
• Rising Parkinson's disease population globally, particularly among adults aged 60+.
• Increasing duration of levodopa use, leading to higher incidence of LID in advanced PD patients.
• Strong demand for adjunct therapies that reduce dyskinesia severity without compromising motor benefits of levodopa.
• Expanding pipeline of glutamate receptor modulators, serotonergic stabilizers, and gene-based approaches.
• Growing awareness among neurologists about managing motor complications early in therapy.

Restraints
• Limited number of FDA-approved therapies specifically targeting LID.
• High cost of branded add-on therapies such as Gocovri (amantadine ER).
• Variability in LID severity makes standardized treatment challenging.
• Adverse effects associated with amantadine-based medications (hallucinations, confusion, edema).
• Limited treatment options for patients with rapidly progressing LID.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71914/parkinson-s-disease-levodopa-induced-dyskinesia-market

Opportunities
• Development of next-generation NMDA antagonists and serotonergic system modulators.
• Rapid technological progress in deep brain stimulation (DBS) optimization.
• Rising interest in personalized therapy combining medication and device-based approaches.
• AI-driven monitoring tools enabling continuous assessment of dyskinesia severity.
• Growth in research on gene therapy and disease-modifying treatments for Parkinson's disease.

Market Growth Outlook (2024-2034)
The LID market is projected to rise from USD 410 million in 2024 to USD 760 million in 2034, supported by strong adoption of amantadine-based therapies, emergence of novel pharmacological agents, and increasing PD patient burden.
Advancements in neuromodulation and targeted molecular therapies are expected to reshape LID management over the next decade.

Segmentation Analysis
By Treatment Type
Pharmacological Treatments:
• Amantadine-based therapies (Gocovri, Osmolex ER) remain the primary approved option for reducing dyskinesia.
• Anti-glutamatergic agents targeting NMDA receptors show promising clinical results.
• Serotonin system modulators are emerging as potential candidates for stabilizing dopamine release.
• Dopamine stabilizers and novel small molecules are progressing through clinical development.

Device-Based Treatments:
• Deep Brain Stimulation (DBS) of the subthalamic nucleus or globus pallidus interna can reduce dyskinesia severity in advanced PD patients.
• Advanced DBS platforms with closed-loop stimulation improve precision and motor control.

By End User
• Hospitals & Neurology Centers provide comprehensive PD care, including DBS therapy and advanced monitoring.
• Movement Disorder Clinics specialize in managing motor fluctuations and providing long-term follow-up.
• Home-Care Settings & Digital Platforms support medication adherence, symptom tracking, and tele-neurology consultations.

Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71914

Regional Insights
North America
North America dominates the LID market due to strong adoption of advanced PD therapies, widespread use of amantadine ER, high prevalence of PD, and availability of cutting-edge DBS systems. The U.S. remains the largest market globally.

Europe
Europe holds a substantial share supported by established PD care networks, reimbursed LID treatments, and rising adoption of neuromodulation technologies. Germany, France, the UK, and Italy are major contributors.

Asia Pacific
Asia Pacific is the fastest-growing region, driven by rising aging populations, increasing PD prevalence, rapid improvement in neurology infrastructure, and growing access to device-based therapies in Japan, South Korea, China, and Australia.

Latin America & Middle East/Africa
Growth in these regions is steady but constrained by limited access to specialized movement-disorder neurologists and advanced therapeutic technologies.

Competitive Landscape
The LID market includes pharmaceutical innovators, neuromodulation technology companies, and research organizations developing advanced PD therapies.

Key Companies Include:
• Adamas Pharmaceuticals (now part of Supernus Pharmaceuticals)
• Supernus Pharmaceuticals
• Novartis
• Merck
• AbbVie
• Pfizer
• Teva Pharmaceutical Industries
• Medtronic (DBS systems)
• Boston Scientific (neuromodulation technologies)
• AbbVie (device combination therapies)

These companies focus on NMDA antagonists, serotonergic modulators, novel PD adjunct drugs, and precision neuromodulation systems.

Recent Developments
• Continued adoption of Gocovri as the leading FDA-approved LID therapy.
• Advancements in closed-loop DBS technologies improving dyskinesia control.
• Progress in NMDA receptor modulators and next-generation anti-dyskinetic drugs in clinical trials.
• Increasing exploration of serotonergic system modulation as a key LID treatment strategy.
• Expansion of AI-based movement tracking tools for real-time dyskinesia monitoring.

This report is also available in the following languages : Japanese (パーキンソン病レボドパ誘発性ジスキネジア市場), Korean (파킨슨병 레보도파 유발 디스키네시아 시장), Chinese (帕金森病左旋多巴诱发运动障碍市场), French (Marché de la dyskinésie induite par la lévodopa dans la maladie de Parkinson), German (Markt für Levodopa-induzierte Dyskinesien bei Parkinson-Krankheit), and Italian (Mercato della discinesia indotta dalla levodopa nel morbo di Parkinson), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71914

Our More Reports:

Pediatric Relapsed-Refractory Neuroblastoma Market
https://exactitudeconsultancy.com/reports/71633/pediatric-relapsed-refractory-neuroblastoma-market

Glioma Market
https://exactitudeconsultancy.com/reports/71635/glioma-market

Metastatic HER2+ve Breast Cancer Patient Pool Analysis Market
https://exactitudeconsultancy.com/reports/71637/metastatic-her2-ve-breast-cancer-patient-pool-analysis-market

Extensive-Stage Small Cell Lung Cancer Market
https://exactitudeconsultancy.com/reports/71639/extensive-stage-small-cell-lung-cancer-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.